U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859099) titled 'Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP' on Feb. 27.
Brief Summary: This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant wil...